QUETIAPINE AND OLANZAPINE FOR TREATMENT OF PSYCHOSIS IN PEOPLE WITH VASCULAR DEMENTIA

QUETIAPINE AND OLANZAPINE FOR TREATMENT OF PSYCHOSIS IN PEOPLE WITH VASCULAR DEMENTIA

Authors

  • RUMIYA ZAKARIYYA KARIMOVA

DOI:

https://doi.org/10.52340/jecm.2022.07.33

Keywords:

vascular dementia, psychotic symptoms, delusions, hallucinations, neuroleptics

Abstract

Along with the aging of the world population, the number of people suffering from dementia is also increasing. Dementia has many types. Dementia of vascular origin takes the 2nd place in terms of prevalence in the world. When we think of vascular dementia, the first thing that comes to mind is cognitive decline. However, it is the non-cognitive disorders that separate further the patient from society and worry the relatives of the patient more. Today, few drugs are recommended for their treatment. But their use is also limited due to side effects. Even according to many studies, no neuroleptics treat these symptoms. Our study compared the effects of olanzapine and quetiapine on non-cognitive symptoms. It was concluded that both drugs treat psychotic symptoms in small doses. The results of the effects of these drugs on other non-cognitive symptoms are presented in our article.

Downloads

Download data is not yet available.

References

Salka S Staekenborg1, Tanja Su1, Elisabeth C W van Straaten1, Roger Lane2, Philip Scheltens1, Frederik Barkhof3, Wiesje M van der Flier1,4, “Behavioural and psychological symptoms in vascular dementia; differences between small- and large-vessel disease”, https://jnnp.bmj.com/content/81/5/547.short)

Gupta M, Dasgupta A, Khwaja GA, Chowdhury D, Patidar Y, Batra A.Behavioural and psychological symptoms in poststroke vascular cognitive impairment. Behav Neurol. 2014;2014:430128. doi: 10.1155/2014/430128. Epub 2014 Mar 2.

Siafarikas N, Selbaek G, Fladby T, Šaltytė Benth J, Auning E, Aarsland D. Frequency and subgroups of neuropsychiatric symptoms in mild cognitive impairment and different stages of dementia in Alzheimer's disease. Int Psychogeriatr. 2018 Jan;30(1):103-113. doi: 10.1017/S1041610217001879. Epub 2017 Sep 20. PMID: 28927477.

Rattinger GB, Schwartz S, Mullins CD, Corcoran C, Zuckerman IH, Sanders C, Norton MC, Fauth EB, Leoutsakos JM, Lyketsos CG, Tschanz JT. Dementia severity and the longitudinal costs of informal care in the Cache County population. Alzheimers Dement. 2015 Aug;11(8):946-54. doi: 10.1016/j.jalz.2014.11.004. Epub 2015 Jan 19. PMID: 25614127; PMCID: PMC4506892.

Wübker A, Zwakhalen SM, Challis D, Suhonen R, Karlsson S, Zabalegui A, Soto M, Saks K, Sauerland D. Costs of care for people with dementia just before and after nursing home placement: primary data from eight European countries. Eur J Health Econ. 2015 Sep;16(7):689-707. doi: 10.1007/s10198-014-0620-6. Epub 2014 Jul 29. PMID: 25069577.

Banerjee S. The use of antipsychotic medication for people with dementia: time for action. – 2009.

Chiesa D, Marengoni A, Nobili A, Tettamanti M, Pasina L, Franchi C, Djade CD, Corrao S, Salerno F, Marcucci M, Romanelli G, Mannucci PM; REPOSI Investigators. Antipsychotic prescription and mortality in hospitalized older persons. Psychogeriatrics. 2017 Nov;17(6):397-405. doi: 10.1111/psyg.12263. Epub 2017 Jun 6. PMID: 28589693.Newman M Zainal N The value of maintaining social connections for mental health in older people. Lancet Public Health. 2020; 5: e12-e13.

Raivio MM, Laurila JV, Strandberg TE, Tilvis RS, Pitkälä KH. Neither atypical nor conventional antipsychotics increase mortality or hospital admissions among elderly patients with dementia: a two-year prospective study. Am J Geriatr Psychiatry. 2007 May;15(5):416-24. doi: 10.1097/JGP.0b013e31802d0b00. PMID: 17463191.

Mühlbauer V, Möhler R, Dichter MN, Zuidema SU, Köpke S, Luijendijk HJ. Antipsychotics for agitation and psychosis in people with Alzheimer's disease and vascular dementia. Cochrane Database Syst Rev. 2021 Dec 17;12(12):CD013304. doi: 10.1002/14651858.CD013304.pub2. PMID: 34918337; PMCID: PMC8678509.

Ralph SJ, Espinet AJ. Increased All-Cause Mortality by Antipsychotic Drugs: Updated Review and Meta-Analysis in Dementia and General Mental Health Care. J Alzheimers Dis Rep. 2018 Feb 2;2(1):1-26. doi: 10.3233/ADR-170042. PMID: 30480245; PMCID: PMC6159703.

Downloads

Published

2022-10-27

How to Cite

KARIMOVA, R. Z. . (2022). QUETIAPINE AND OLANZAPINE FOR TREATMENT OF PSYCHOSIS IN PEOPLE WITH VASCULAR DEMENTIA. Experimental and Clinical Medicine Georgia, (7). https://doi.org/10.52340/jecm.2022.07.33

Issue

Section

Articles
Loading...